For The Latest Medical News, Health News, Research News, COVID-19 News, Pharma News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Thailand Cannabis News, Cancer News, Doctor News, Thailand Hospital News, Oral Cancer News, Thailand Doctors

BREAKING NEWS
Source: Thailand Medical News  Nov 23, 2019  6 years, 2 months, 1 week, 1 day, 21 hours, 57 minutes ago

Cancer Diagnostics Startup, Lucence Raises US $20M In Series A Funding

Presented by
Cancer Diagnostics Startup, Lucence Raises US $20M In Series A Funding
Source: Thailand Medical News  Nov 23, 2019  6 years, 2 months, 1 week, 1 day, 21 hours, 57 minutes ago
Cancer Diagnostics Startup, Lucence announced on Tuesday the closing of its Series A financing round, bringing in US $20 million.


Tan Min-Han CEO and Medical Director Lucence Diagnostics 

Investors IHH Healthcare led the round and was joined by SGInnovate and existing investors Temasek Holdings subsidiary Heliconia Capital, Lim Kaling, Koh Boon Hwee, and others. Lucence said the funding will allow it to expand access to its liquid biopsy test to more patients in Asia and North America. It added that it plans to conduct new prospective clinical studies to evaluate its technology for the early detection of multiple cancers.

Startup Lucence is based in Singapore and has offices in San Francisco, Hong Kong, and Suzhou, China.

The startup began offering its flagship test, the LiquidHallMark liquid biopsy panel, a year ago for cancer-related gene mutations and cancer-causing viruses in one assay. The next-generation sequencing-based test detects clinically relevant mutations across 14 cancer types, including lung, breast, colorectal, pancreatic, nasopharyngeal, and liver cancers, it said.

In September 2019, Lucence's Singapore lab received CLIA certification. The lab is also accredited by the College of American Pathologists. Earlier this month, it and China's MEDx (Suzhou) Translational Medicine announced an agreement to codevelop companion diagnostic tests for PD-L1 rearrangements to be used with anti-PD1/PD-L1 cancer immunotherapies.

MOST READ

Jan 27, 2026  6 days ago
Nikhil Prasad
Jan 27, 2026  6 days ago
Nikhil Prasad
Jan 26, 2026  7 days ago
Nikhil Prasad
Jan 25, 2026  8 days ago
Nikhil Prasad
Jan 24, 2026  9 days ago
Nikhil Prasad
Jan 23, 2026  10 days ago
Nikhil Prasad
Jan 22, 2026  11 days ago
Nikhil Prasad
Jan 21, 2026  12 days ago
Nikhil Prasad
Jan 20, 2026  13 days ago
Nikhil Prasad
Jan 18, 2026  15 days ago
Nikhil Prasad
Jan 18, 2026  15 days ago
Nikhil Prasad
Jan 17, 2026  16 days ago
Nikhil Prasad
Jan 14, 2026  19 days ago
Nikhil Prasad
Jan 14, 2026  19 days ago
Nikhil Prasad
Jan 13, 2026  20 days ago
Nikhil Prasad
Jan 12, 2026  21 days ago
Nikhil Prasad
Jan 12, 2026  21 days ago
Nikhil Prasad
Jan 11, 2026  22 days ago
Nikhil Prasad
Jan 09, 2026  24 days ago
Nikhil Prasad